Enbrel (etanercept) is a protein pharmaceutical. Etanercept was first approved as Enbrel on 1998-11-02. It is used to treat ankylosing spondylitis, juvenile arthritis, psoriatic arthritis, and rheumatoid arthritis in the USA. It has been approved in Europe to treat ankylosing spondylitis, juvenile arthritis, psoriasis, psoriatic arthritis, and rheumatoid arthritis amongst others. The pharmaceutical is active against tumor necrosis factor. In addition, it is known to target lymphotoxin-alpha.
|Indication||ankylosing spondylitis, juvenile arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, spondylarthropathies|
|Drug Class||Receptor molecules, native or modified: tumor necrosis factor receptors|